TLC-2716
TLC-2716 has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Jan 16, 2026: “An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trial”.
1 paper studies it4 findingsUpdated
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country; 1 trial, none about aging.
“resulted in placebo-adjusted reductions up to 38.5% in plasma TG”
None of its findings points the other way.
- 1 lab in 1 country
- 1 trial, none about aging
- Funders: École Polytechnique Fédérale de Lausanne and 6 more
- 4 of 4 findings with company ties
- 1 of 1 trial sponsored by its developers
- Human trial1
Studies in people
1 study gave TLC-2716 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases lipid accumulation down: Decreases triglycerideplacebo-adjusted reductions up to 38.5% down: Decreases remnant cholesterolplacebo-adjusted reductions up to 61% | Randomized trial14-day | Steatohepatitis model | Nature medicine, Jan 16, 2026 |
What did studies of TLC-2716 find?
4Studies of TLC-2716 measured 4 outcomes, among them remnant cholesterol, triglyceride and inflammation.
Remnant cholesterol
downin humans1
1 study
Remnant cholesterol
downin humans1
TLC-2716 decreases remnant cholesterol in humans (placebo-adjusted reductions up to 61%).
“and 61% in postprandial remnant cholesterol”
Human trial14-day
Nature medicine
Triglyceride
downin humans1
1 study
Triglyceride
downin humans1
TLC-2716 decreases triglyceride in humans (placebo-adjusted reductions up to 38.5%).
“resulted in placebo-adjusted reductions up to 38.5% in plasma TG”
Human trial14-day
Nature medicine
Inflammation
downin human cells1
1 study
Inflammation
downin human cells1
TLC-2716 decreases inflammation in human cells (steatohepatitis model).
“TLC-2716 reduced lipid accumulation and suppressed inflammation and fibrotic gene expression.”
Cellssteatohepatitis modelliver
Nature medicine
Lipid accumulation
downin human cells1
1 study
Lipid accumulation
downin human cells1
TLC-2716 decreases lipid accumulation in human cells (steatohepatitis model).
“TLC-2716 reduced lipid accumulation and suppressed inflammation and fibrotic gene expression.”
Cellssteatohepatitis modelliver
Nature medicine
Who is developing TLC-2716?
1 company: OrsoBio.
- Companies
- OrsoBioPhase 1
Trial sponsors
Company1 trialPhase 1100 people